Discovery and development of purine-scaffold Hsp90 inhibitors

Current Topics in Medicinal Chemistry

Volumn 6, Issue 11, 2006, Pages 1183-1191

  Chiosis, Gabriela ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

8 sulfanylpurines; Hsp90 inhibitors; N terminal ATPase pocket; Purine scaffold; Tumor growth

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; CNF 1010; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HORMONE RECEPTOR; IPI 504; KOS 953; MUTANT PROTEIN; NATURAL PRODUCT; NEOPENTYLAMINE; ONCOPROTEIN; PHOSPHOTRANSFERASE; PURINE DERIVATIVE; TERT BUTYLAMINE DERIVATIVE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GASTROINTESTINAL HEMORRHAGE; HUMAN; IC 50; LIVER TOXICITY; NONHUMAN; PROTEIN FUNCTION; REVIEW; STOMACH CANCER; STRUCTURE ACTIVITY RELATION;

ADENINE; ANIMALS; ANISOLES; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; PURINES;

EID: 33746365169     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606777812013     Document Type: Review

References (42)

1. Workman, P.; Maloney, A. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2002, 2, 3-24.
2. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. Therapeutic and diagnostic implications of Hsp9O activation. Trends Mol. Med. 2004, 10, 283-290.
3. Neckers, L.; Neckers, K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin. Emerg. Drugs 2005, 1, 137-149.
4. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 10, 761-772.
5. Chiosis, G. Modulating chaperones in transformed systems - a focus on Hsp90 and cancer. Expert Opin. Ther. Targets 2006, 10, 37-50.
6. Neckers, L.; Schulte, T. W.; Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest. New Drugs 1999, 17, 361-373
7. Soga, S.; Shiotsu, Y.; Akinaga, S.; Sharma, S. V. Development of radicicol analogues. Curr. Cancer Drug Targets 2003, 3, 359-369.
8. Baneiji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M.; Walton, M.; Lakhani, S.; Kaye, S.; Workman, P.; Judson, I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 4152-4161
9. Ramanathan, R. K; Trump, D. L.; Eiseman, J. L.; Belani, C. P.; Agarwala, S. S.; Zuhowski, E. G.; Lan, J.; Potter, D. M.; Ivy, S. P.; Ramalingam, S.; Brufsky, A. M.; Wong, M. K.; Tutchko, S.; Egorin, M. J. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res. 2005, 11, 3385-3391.
10. Goetz, M. P.; Toft D.; Reid, J.; Ames, M.; Stensgard, B.; Safgren, S.; Adjei, A. A.; Sloan, J.; Atherton, P.; Vasile, V.; Salazaar, S.; Adjei, A.; Croghan, G.; Erlichman, C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 1078-1087.
11. Wegele, H.; Muller, L.; Buchner, J. Hsp70 and Hsp90-a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 2004, 151, 1-44.
12. Prodromou, C.; Pearl, L. H. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets 2003, 3, 301-323.
13. Chene, P. ATPases as drug targets: learning from their structure. Nat. Rev. Drug Discov. 2002, 1, 665-673.
14. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hard, U.; Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 1997, 89, 239-250.
15. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42, 260-266.
16. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425, 407-410.
17. Janin, Y. L. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J. Med. Chem. 2005, 48, 7503-75120
18. Chiosis, G.; Rodina, A.; Moulick, K. Emerging Hsp90 inhibitors: From discovery to clinic. Anti-Cancer Agents Med. Chem. 2006, 6, 1-8.
19. Blagg, B. S.; Kerr, T. D. Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med. Res. Rev. 2006, 26(3), 310-38.
20. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen N. A Small Molecule Designed to Bind to the Adenine Nucleotide Pocket of Hsp90 Causes Her2 Degradation and the Growth Arrest and Differentiation of Breast Cancer Cells. Chem. Biol 2001, 8, 289-299.
21. Chiosis, G.; Rosen, N. Small molecule composition for binding to Hsp90. WO 0236075, 2002.
22. Chiosis, G.; Lucas, B.; Huezo, H.; Solit, D.; Basso, A.; Rosen, N. Development of purine-scaffold small molecule inhibitors of HSp90. Curr. Cancer Drug Targets 2003, 3, 363-368.
23. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen N. Development of a Purine-based Novel Class of Hsp90 Binders That Inhibit the Proliferation of Cancer Cells and Induce the Degradation of Her2 Tyrosine Kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
24. Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 2004, 6, 775-785.
25. Kasibhatla, S. R.; Zhang, L.; Boehm, M. F.; Fan, J.; Hong, K.; Shi, J.; Biamonte, M. A. Purine Analogues Having Hsp90 Inhibiting Activity. WO 3037860, 2003.
26. Llauger, L.; He, H.; Kim, J.; Aguirre, J.; Rosen, N.; Peters, U.; Davies, P.; Chiosis, G. 8-Arylsulfanyl and 8-Arylsulfoxyl Adenine Derivatives as Inhibitors of the Heat Shock Protein 90. J. Med. Chem. 2005, 48, 2892-2905.
27. Biamonte, M. A.; Shi, J.; Hong, K.; Hurst, D. C.; Zhang, L.; Fan, J.; Busch, D. J.; Kaijian, P. L.; Maldonado, A. A.; Sensintaffar, J. L.; Yang, Y-C.; Kamal, A.; Lough, R. E.; Lundgren, K.; Burrows, F. J.; Timony, G. A.; Boehm, M. F.; Kasibhatla, S. R. Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90. J. Med. Chem. 2006, 49, 817-828.
28. He, H.; Zatorska, D.; Kim, J.; Aguirre, J.; Llauger, L.; She, Y.; Wu, N.; Immormino, R. M.; Gewirth, D. T.; Chiosis, G. Identification of Potent Water Soluble Purine-Scaffold Inhibitors of the Heat Shock Protein 90. J. Med. Chem. 2006, 49, 381-390.
29. Kasibhatla, S. R.; Hong, D. K.; Boehm, M. F.; Biamonte, M. A.; Zhang, L. 2-aminopurine analogs having Hsp90-inhibiting activity. US Appl. 2005/ 0113340.
30. Bork, J. T.; Lee, J. W.; Chang, Y. T. The combinatorial synthesis of purine, pyrimidine, and triazine-based libraries, QSAR Comb. Sci. 2004, 23, 245-260.
31. Dymock B.; Barril, X.; Beswick, M.; Collier, A.; Davies, N.; Drysdale, M.; Fink, A.; Fromont, C.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 2004, 2, 325-328.
32. He, H.; Llauger, L.; Rosen, N.; Chiosis, G. General method for the synthesis of 8-arylsulfanyl adenine derivatives. J. Org. Chem. 2004 69, 3230-3232.
33. Chiosis, G.; Rosen, N.; Huezo, H. Assay For Identification Of Bioactive Compounds That Interact With Heat Shock Protein 90. WO012482, 2005.
34. Kamal, A.; Burrows, F. J.; Zhang L.; Boehm, M. F. Assays and implements for determining and modulating hsp90 binding activity. US074457, 2005.
35. Xu, W.; Mimnaugh, E.; Rosser, M. F.; Nicchitta, C.; Marcu, M.; Yarden, Y.; Neckers, L. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J. Biol. Chem. 2001, 276, 3702-3708.
36. Srethapakdi, M.; Liu, F.; Tavorath, R.; Rosen, N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma. gene product-dependent G1 arrest. Cancer Res. 2000, 60, 3940-3946.
37. Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen, N.; Spampinato, C.; Modrich, P.; Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCI, a specific inhibitor of tumor Hsp90. Chem. Biol. 2004, 11, 787-797.
38. Eiseman, J. L.; Lan, J.; Lagattuta, T. F.; Hamburger, D. R.; Joseph, E.; Covey, J. M.; Egorin, M. J. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17- (2-dimedlylamino)ethyl] amino] geldanamycin (17DMAG, NS C 707545) in C.B-17 SCID mice bearing NMA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 2005, 55, 21-32.
39. Banerji, U.; Walton, M., Raynaud, F.; Grimshaw, R.; Kelland, L.; Valenti, M.; Judson, I.; Workman, P. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin. Cancer Res. 2005, 11, 7023-7032.
40. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1999, 244, 707-712.
41. Hilger, R. A.; Scheulen, M. E.; Strumberg, D. The Ras-Raf-MEKERK pathway in the treatment of cancer. Onkologie 2002, 25, 511-518.
42. Chang, F.; Lee, J. T.; Navolanic, P. M.; Steelman, L. S.; Shelton, J. G.; Blalock, W. L.; Franklin, R. A.; McCubrey, J. A. Involvement of P13K/ Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17, 590-603.